AAML1331: A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

Protocol: 
AAAR3160
Phase: 
III

AAML1331: A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

Are you Eligible? (Inclusion Criteria)

-Subjects must be at least 1 year and up to 21 years of age at the time of
study entry.
-Patients must be newly diagnosed with acute promyelocytic leukemia.
-Patients must also meet all eligibility criteria as outlined in the study
protocol.

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States